Skip to main content

Advertisement

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Page 8 of 11

  1. Chk1 inhibitors are currently in clinical trials as putative potentiators of cytotoxic chemotherapy drugs. Chk1 inhibitors may exhibit single agent anti-tumor activity in cancers with underlying DNA repair, DN...

    Authors: Christopher Bryant, Rebecca Rawlinson and Andrew J Massey

    Citation: BMC Cancer 2014 14:570

    Content type: Research article

    Published on:

  2. We previously reported that 3'-ethynylcytidine (ECyd, TAS-106), an RNA polymerases inhibitor, enhances the anti-tumor efficacy of platinum in several tumor types in both in vitro and in vivo tumor models. However...

    Authors: Hiroto Fukushima, Tetsuya Abe, Kazuki Sakamoto, Hiroaki Tsujimoto, Shinji Mizuarai and Shinji Oie

    Citation: BMC Cancer 2014 14:562

    Content type: Research article

    Published on:

  3. Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular activ...

    Authors: Takahiro Yamauchi, Kanako Uzui, Rie Nishi, Hiroko Shigemi and Takanori Ueda

    Citation: BMC Cancer 2014 14:547

    Content type: Research article

    Published on:

  4. Because oestrogen receptor α (ERα) regulates E2F1 expression to mediate tamoxifen resistance in ERα-positive breast cancer cells, we aimed to define the possible roles of ERα and E2F1 in promoting the resistan...

    Authors: María F Montenegro, María del Mar Collado-González, María Piedad Fernández-Pérez, Manel B Hammouda, Lana Tolordava, Mariam Gamkrelidze and José Neptuno Rodríguez-López

    Citation: BMC Cancer 2014 14:539

    Content type: Research article

    Published on:

  5. Ionizing radiation (IR) is a mainstay of cancer therapy, but irradiation can at times also lead to stress responses, which counteract IR-induced cytotoxicity. IR also triggers cellular secretion of vascular en...

    Authors: Colette J Shen, Ashish Sharma, Dinh-Van Vuong, Janine T Erler, Martin Pruschy and Angela Broggini-Tenzer

    Citation: BMC Cancer 2014 14:532

    Content type: Research article

    Published on:

  6. Metals including iron, copper and zinc are essential for physiological processes yet can be toxic at high concentrations. However the role of these metals in the progression of cancer is not well defined. Here...

    Authors: Maamoun Fatfat, Raghida Abou Merhi, Omar Rahal, Detcho A Stoyanovsky, Angela Zaki, Hazar Haidar, Valerian E Kagan, Hala Gali-Muhtasib and Khaled Machaca

    Citation: BMC Cancer 2014 14:527

    Content type: Research article

    Published on:

  7. Chk1 inhibitors are currently in clinical trials in combination with a range of cytotoxic agents and have the potential to potentiate the clinical activity of a large number of standard of care chemotherapeuti...

    Authors: Rebecca Rawlinson and Andrew J Massey

    Citation: BMC Cancer 2014 14:483

    Content type: Research article

    Published on:

  8. The combination of virotherapy and chemotherapy may enable efficient tumor regression that would be unachievable using either therapy alone. In this study, we investigated the efficiency of transgene delivery ...

    Authors: Anna Zajakina, Jelena Vasilevska, Dmitry Zhulenkovs, Dace Skrastina, Artjoms Spaks, Aiva Plotniece and Tatjana Kozlovska

    Citation: BMC Cancer 2014 14:460

    Content type: Research article

    Published on:

  9. Clear cell sarcoma (CCS) is a therapeutically unresolved, aggressive, soft tissue sarcoma (STS) that predominantly affects young adults. This sarcoma is defined by t(12;22)(q13;q12) translocation, which leads ...

    Authors: Hidetatsu Outani, Takaaki Tanaka, Toru Wakamatsu, Yoshinori Imura, Kenichiro Hamada, Nobuhito Araki, Kazuyuki Itoh, Hideki Yoshikawa and Norifumi Naka

    Citation: BMC Cancer 2014 14:455

    Content type: Research article

    Published on:

  10. Glioblastomas are largely unresponsive to all available treatments and there is therefore an urgent need for novel therapeutics. Here we have probed the antineoplastic effects of a bacterial protein toxin, the...

    Authors: Eleonora Vannini, Anna Panighini, Chiara Cerri, Alessia Fabbri, Simonetta Lisi, Enrico Pracucci, Nicola Benedetto, Riccardo Vannozzi, Carla Fiorentini, Matteo Caleo and Mario Costa

    Citation: BMC Cancer 2014 14:449

    Content type: Research article

    Published on:

  11. The aim of this study was to evaluate the efficacy of the p53-reactivating drugs RITA and nutlin3a in killing myeloma cells.

    Authors: Sylvanie Surget, Géraldine Descamps, Carole Brosseau, Vincent Normant, Sophie Maïga, Patricia Gomez-Bougie, Nadège Gouy-Colin, Catherine Godon, Marie C Béné, Philippe Moreau, Steven Le Gouill, Martine Amiot and Catherine Pellat-Deceunynck

    Citation: BMC Cancer 2014 14:437

    Content type: Research article

    Published on:

  12. A common approach to cancer therapy in clinical practice is the combination of several drugs to boost the anticancer activity of available drugs while suppressing their unwanted side effects. In this regard, w...

    Authors: Hye-Kyung Park, Ji-Eun Lee, Jaehwa Lim, Da-Eun Jo, Soo-Ah Park, Pann-Ghill Suh and Byoung Heon Kang

    Citation: BMC Cancer 2014 14:431

    Content type: Research article

    Published on:

  13. Tumorigenesis is the result of genomic or epigenomic insults and subsequent loss of the proper mechanisms to respond to these alterations leading to unscheduled growth. Tumors arising from these mutations ofte...

    Authors: William N Pappano, Qian Zhang, Lora A Tucker, Chris Tse and Jieyi Wang

    Citation: BMC Cancer 2014 14:430

    Content type: Research article

    Published on:

  14. Breast cancer is one of the most deadly diseases in women. Inhibiting the synthesis of estrogen is effective in treating patients with estrogen-responsive breast cancer. Previous studies have demonstrated that...

    Authors: Tsz Yan Wong, Fengjuan Li, Shu-mei Lin, Franky L Chan, Shiuan Chen and Lai K Leung

    Citation: BMC Cancer 2014 14:426

    Content type: Research article

    Published on:

  15. Activation of Rho, one of the small GTPases, and its major downstream target Rho-kinase (ROCK) promotes the development and metastasis of cancer. We previously showed that elevation of Rho and ROCK expression ...

    Authors: Hideyuki Abe, Takao Kamai, Keitaro Hayashi, Naohiko Anzai, Hiromichi Shirataki, Tomoya Mizuno, Yoshiyuki Yamaguchi, Akinori Masuda, Hideo Yuki, Hironori Betsunoh, Masahiro Yashi, Yoshitatsu Fukabori and Ken-Ichiro Yoshida

    Citation: BMC Cancer 2014 14:412

    Content type: Research article

    Published on:

  16. Development of escape pathways from antiangiogenic treatments was reported to be associated with enhanced tumor aggressiveness and rebound effect was suggested after treatment stop. Aim of the study was to eva...

    Authors: Sara Marinelli, Veronica Salvatore, Marco Baron Toaldo, Maddalena Milazzo, Luca Croci, Laura Venerandi, Anna Pecorelli, Chiara Palamà, Alessia Diana, Luigi Bolondi and Fabio Piscaglia

    Citation: BMC Cancer 2014 14:403

    Content type: Research article

    Published on:

  17. Photoimmunotherapy (PIT) is a highly cell-selective cancer therapy, which employs monoclonal antibodies conjugated to a potent photosensitizer (mAb-IR700). Once the conjugate has bound to the target cell, expo...

    Authors: Takahito Nakajima, Kazuhide Sato, Hirofumi Hanaoka, Rira Watanabe, Toshiko Harada, Peter L Choyke and Hisataka Kobayashi

    Citation: BMC Cancer 2014 14:389

    Content type: Research article

    Published on:

  18. Pancreatic cancer is one of the most aggressive human malignancies with a extremely low 5-year survival rate. Hence, the search for more effective anti-pancreatic cancer agents is urgent.

    Authors: Xing-dong Xu, Lan Yang, Li-yun Zheng, Yan-yan Pan, Zhi-fei Cao, Zhi-qing Zhang, Quan-sheng Zhou, Bo Yang and Cong Cao

    Citation: BMC Cancer 2014 14:373

    Content type: Research article

    Published on:

    The Erratum to this article has been published in BMC Cancer 2016 16:374

  19. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is reported to exert anti-tumor effects by upregulating the expression of the natural killer group 2D (NKG2D) ligands on tumor cells; however, the m...

    Authors: Pengfei Shi, Tao Yin, Feng Zhou, Pengfei Cui, Shanmiao Gou and Chunyou Wang

    Citation: BMC Cancer 2014 14:370

    Content type: Research article

    Published on:

  20. Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with limited therapeutic options. Since HCC has been shown to be immunogenic, immunotherapy is considered a promising therapeutic...

    Authors: Tatyana O Kabilova, Larisa V Kovtonyuk, Evgeniy V Zonov, Elena I Ryabchikova, Nelly A Popova, Valeriy P Nikolin, Vasiliy I Kaledin, Marina A Zenkova, Valentin V Vlassov and Elena L Chernolovskaya

    Citation: BMC Cancer 2014 14:338

    Content type: Research article

    Published on:

  21. The small size of ultra-small nanoparticles makes them suitable for lymphatic delivery, and many recent studies have examined their role in anti-metastasis therapy. However, the anti-metastatic efficacy of sma...

    Authors: Yunfei Li, Mingji Jin, Shuai Shao, Wei Huang, Feifei Yang, Wei Chen, Shenghua Zhang, Guimin Xia and Zhonggao Gao

    Citation: BMC Cancer 2014 14:329

    Content type: Research article

    Published on:

  22. Oesophageal squamous cell carcinoma (OSCC) is a highly aggressive carcinoma with a poor survival rate. One of the most commonly used chemotherapeutic drugs, cisplatin, displays varied and often poor efficacy i...

    Authors: Leonard Howard Damelin, Rupal Jivan, Robin Bruce Veale, Amanda Louise Rousseau and Demetra Mavri-Damelin

    Citation: BMC Cancer 2014 14:314

    Content type: Research article

    Published on:

  23. Androgen deprivation therapy is the primary strategy for the treatment of advanced prostate cancer; however, after an initial regression, most patients will inevitably develop a fatal androgen-independent tumo...

    Authors: Xiaolu Wang, Haitao Gao, Lixin Ren, Junfei Gu, Yanping Zhang and Yong Zhang

    Citation: BMC Cancer 2014 14:308

    Content type: Research article

    Published on:

  24. Expression and function of sodium iodide symporter (NIS) is requisite for efficient iodide transport in thyrocytes, and its presence in cancer cells allows the use of radioiodine as a diagnostic and therapeuti...

    Authors: Salvatore Micali, Stefania Bulotta, Cinzia Puppin, Angelo Territo, Michele Navarra, Giampaolo Bianchi, Giuseppe Damante, Sebastiano Filetti and Diego Russo

    Citation: BMC Cancer 2014 14:303

    Content type: Review

    Published on:

  25. Surgical therapies are the first-line treatments for hepatocellular carcinoma (HCC) patients. However, the high incidence of tumor metastasis after liver surgery remains a severe problem. We aim to investigate...

    Authors: Chang Xian Li, Bing L Wong, Chang Chun Ling, Yuen Yuen Ma, Yan Shao, Wei Geng, Xiang Qi, Sze Hang Lau, Sui Yi Kwok, Na Wei, Fei Chuen Tzang, Kevin TP Ng, Xiao Bing Liu, Chung Mau Lo and Kwan Man

    Citation: BMC Cancer 2014 14:293

    Content type: Research article

    Published on:

  26. Zalypsis® is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing’s sarcoma. However, the determinants of the response to Zalypsis are not well known. ...

    Authors: Victoria Moneo, Beatriz G Serelde, Carmen Blanco-Aparicio, Ramon Diaz-Uriarte, Pablo Avilés, Gemma Santamaría, Juan C Tercero, Carmen Cuevas and Amancio Carnero

    Citation: BMC Cancer 2014 14:281

    Content type: Research article

    Published on:

  27. Cholangiocarcinoma (CCA), a devastating neoplasm, is highly resistant to current chemotherapies. CCA cells frequently overexpress the antiapoptotic protein myeloid cell leukemia-1(Mcl-1), which is responsible ...

    Authors: Xiwei Ding, Bin Zhang, Qingshan Pei, Jianmei Pan, Shuling Huang, Yan Yang, Zhu Zhu, Ying Lv and Xiaoping Zou

    Citation: BMC Cancer 2014 14:271

    Content type: Research article

    Published on:

  28. Gallbladder cancer is the most frequent malignancy of the bile duct with high aggressive and extremely poor prognosis. The main objective of the paper was to investigate the inhibitory effects of oridonin, a d...

    Authors: Runfa Bao, Yijun Shu, Xiangsong Wu, Hao Weng, Qian Ding, Yang Cao, Maolan Li, Jiasheng Mu, Wenguang Wu, Qichen Ding, Zhujun Tan, Tianyu Liu, Lin Jiang, Yunping Hu, Jianfeng Gu and Yingbin Liu

    Citation: BMC Cancer 2014 14:217

    Content type: Research article

    Published on:

  29. Medulloblastoma is the most common type of pediatric brain tumor. Although numerous factors influence patient survival rates, more than 30% of all cases will ultimately be refractory to conventional therapies....

    Authors: Brian Hutzen, Hemant Kumar Bid, Peter J Houghton, Christopher R Pierson, Kimerly Powell, Anna Bratasz, Corey Raffel and Adam W Studebaker

    Citation: BMC Cancer 2014 14:206

    Content type: Research article

    Published on:

  30. Companion animals like dogs frequently develop tumors with age and similarly to human malignancies, display interpatient tumoral heterogeneity. Tumors are frequently characterized with regard to their mutation...

    Authors: Nicole Grosse, Barbara van Loon and Carla Rohrer Bley

    Citation: BMC Cancer 2014 14:203

    Content type: Debate

    Published on:

  31. Vasculogenic mimicry (VM) is a novel tumor blood supply in some highly aggressive malignant tumors. Recently, we reported VM existed in gallbladder carcinomas (GBCs) and the formation of the special passage th...

    Authors: Jing-Tao Zhang, Wei Sun, Wen-Zhong Zhang, Chun-Yan Ge, Zhong-Yan Liu, Ze-Ming Zhao, Xing-Sui Lu and Yue-Zu Fan

    Citation: BMC Cancer 2014 14:193

    Content type: Research article

    Published on:

  32. Ewing’s sarcoma (ES) is the second most frequent primitive malignant bone tumor in adolescents with a very poor prognosis for high risk patients, mainly when lung metastases are detected (overall survival <15%...

    Authors: Guillaume Odri, Pui-Pui Kim, François Lamoureux, Céline Charrier, Séverine Battaglia, Jérôme Amiaud, Dominique Heymann, François Gouin and Françoise Redini

    Citation: BMC Cancer 2014 14:169

    Content type: Research article

    Published on:

  33. Chemoresistance of glioblastoma multiforme (GBM) has been attributed to the presence within the tumor of cancer stem cells (GSCs). The standard therapy for GBM consists of surgery followed by radiotherapy and ...

    Authors: Lucio Tentori, Lucia Ricci-Vitiani, Alessia Muzi, Fabio Ciccarone, Federica Pelacchi, Roberta Calabrese, Daniele Runci, Roberto Pallini, Paola Caiafa and Grazia Graziani

    Citation: BMC Cancer 2014 14:151

    Content type: Research article

    Published on:

  34. Celastrol is a promising anti-tumor agent, yet it also elevates heat shock proteins (HSPs), especially HSP70, this effect believed to reduce its anti-tumor effects. Concurrent use of siRNA to increase celastro...

    Authors: Bin Peng, Xue Zhang, Fanfan Cao, Ying Wang, Limin Xu, Lu Cao, Chunxin Yang, Maoquan Li, Georges Uzan and Denghai Zhang

    Citation: BMC Cancer 2014 14:146

    Content type: Research article

    Published on:

  35. The anticancer properties of aspirin are restricted by its gastrointestinal toxicity and its limited efficacy. Therefore, we synthesized phospho-aspirin (PA-2; MDC-22), a novel derivative of aspirin, and evalu...

    Authors: Liqun Huang, Chi C Wong, Gerardo G Mackenzie, Yu Sun, Ka Wing Cheng, Kvetoslava Vrankova, Ninche Alston, Nengtai Ouyang and Basil Rigas

    Citation: BMC Cancer 2014 14:141

    Content type: Research article

    Published on:

  36. Identification of new drugs against paediatric sarcomas represents an urgent clinical need that mainly relies on public investments due to the rarity of these diseases. In this paper we evaluated the in vitro and...

    Authors: Clara Guerzoni, Stefano Amatori, Luca Giorgi, Maria Cristina Manara, Lorena Landuzzi, Pier-Luigi Lollini, Aurora Tassoni, Mauro Balducci, Marco Manfrini, Loredana Pratelli, Massimo Serra, Piero Picci, Mauro Magnani, Vieri Fusi, Mirco Fanelli and Katia Scotlandi

    Citation: BMC Cancer 2014 14:137

    Content type: Research article

    Published on:

  37. Hepatocellular carcinoma (HCC) is a primary liver tumor and is the most difficult human malignancy to treat. In this study, we sought to develop an integrative approach in which real-time tumor monitoring, gen...

    Authors: Jing Chen, Shu Zhu, Liangqian Tong, Jiansha Li, Fei Chen, Yunfeng Han, Ming Zhao and Wei Xiong

    Citation: BMC Cancer 2014 14:114

    Content type: Research article

    Published on:

  38. There are a lot of unmet needs in patients with triple-negative breast cancer (TNBC). Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, has been used for decades to treat hypert...

    Authors: Ting Li, Qunling Zhang, Jian Zhang, Gong Yang, Zhimin Shao, Jianmin Luo, Minhao Fan, Chen Ni, Zhenhua Wu and Xichun Hu

    Citation: BMC Cancer 2014 14:96

    Content type: Research article

    Published on:

  39. A subpopulation of tumor cells with distinct stem-like properties (cancer stem-like cells, CSCs) may be responsible for tumor initiation, invasive growth, and possibly dissemination to distant organ sites. CSC...

    Authors: Zhihong Chen, Lora W Forman, Robert M Williams and Douglas V Faller

    Citation: BMC Cancer 2014 14:90

    Content type: Research article

    Published on:

  40. Esterases are often overexpressed in cancer cells and can have chiral specificities different from that of the corresponding normal tissues. For this reason, ester prodrugs could be a promising approach in che...

    Authors: Christopher A McGoldrick, Yu-Lin Jiang, Victor Paromov, Marianne Brannon, Koyamangalath Krishnan and William L Stone

    Citation: BMC Cancer 2014 14:77

    Content type: Research article

    Published on:

  41. Pancreatic adenocarcinoma is one of the most dreaded cancers with very low survival rate and poor prognosis to the existing frontline chemotherapeutic drugs. Gene therapy in combination with a cytotoxic agent ...

    Authors: Jing Xu, Amit Singh and Mansoor M Amiji

    Citation: BMC Cancer 2014 14:75

    Content type: Research article

    Published on:

  42. Triple-negative breast cancer (TNBC) is defined by the absence of expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. Breast cancers with a BRCA1 mutation are a...

    Authors: Tidarat Nhukeaw, Pornvichai Temboot, Kanidtha Hansongnern and Adisorn Ratanaphan

    Citation: BMC Cancer 2014 14:73

    Content type: Research article

    Published on:

  43. Prognosis of adult patients suffering from acute lymphoblastic leukemia (ALL) is still unsatisfactory. Targeted therapy via inhibition of deregulated signaling pathways appears to be a promising therapeutic op...

    Authors: Christin Kretzschmar, Catrin Roolf, Tina-Susann Langhammer, Anett Sekora, Anahit Pews-Davtyan, Matthias Beller, Moritz J Frech, Christian Eisenlöffel, Arndt Rolfs and Christian Junghanss

    Citation: BMC Cancer 2014 14:71

    Content type: Research article

    Published on:

  44. Metformin is an approved drug prescribed for diabetes. Its role as an anti-cancer agent has drawn significant attention because of its minimal side effects and low cost. However, its mechanism of anti-tumour a...

    Authors: Ummuhan Demir, Andrea Koehler, Rainer Schneider, Susann Schweiger and Helmut Klocker

    Citation: BMC Cancer 2014 14:52

    Content type: Research article

    Published on:

  45. Combination therapy is key to improving cancer treatment efficacy. Phorbol 12-myristate 13-acetate (PMA), a well-known PKC activator, increases the cytotoxicity of several anticancer drugs. Apicularen A induce...

    Authors: Kang-Sik Seo, Jong-Seok Kim, Ji-Hoon Park, Kyoung-Sub Song, Eun-Jin Yun, Jong-Il Park, Gi Ryang Kweon, Wan-Hee Yoon, Kyu Lim and Byung-Doo Hwang

    Citation: BMC Cancer 2014 14:36

    Content type: Research article

    Published on:

  46. The targeted delivery of cancer therapeutics represents an ongoing challenge in the field of drug development. TRAIL is a promising cancer drug but its activity profile could benefit from a cancer-selective de...

    Authors: Gunjal Garg, Jesse Gibbs, Brian Belt, Matthew A Powell, David G Mutch, Peter Goedegebuure, Lynne Collins, David Piwnica-Worms, William G Hawkins and Dirk Spitzer

    Citation: BMC Cancer 2014 14:35

    Content type: Research article

    Published on: